Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29th 2021

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Enasidenib Elicits Clinical Efficacy in High-Risk, IDH2-Mutated MDS

July 29th 2021

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.

With Novel Combos on the Horizon, End Points Beyond OS May Hold Promise in HR-MDS

July 28th 2021

Novel combinations with agents, such as pevonedistat, eprenetapopt, venetoclax or magrolimab, plus hypomethylating agents like azacitidine are being evaluated to determine whether they can improve upon the lackluster median survival for patients with higher-risk myelodysplastic syndrome.

Biweekly Cetuximab Offers a Convenient Dosing Option in mCRC

July 27th 2021

Richard Kim, MD, discusses the utility of EGFR inhibitors in patients with RAS wild-type colorectal cancer, the convenience of biweekly dosing with cetuximab, recommendations for managing EGFR inhibitor–related treatment-related adverse effects, and novel combinations on the horizon.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

July 23rd 2021

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors

July 21st 2021

Repetitive locoregional infusion of HER2-specific CAR T cells did not induce any dose-limiting toxicities.

Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma

July 20th 2021

Thomas G. Martin, MD, discusses the latest news in frontline, early relapsed, and heavily pretreated multiple myeloma, including the growing promise of quadruplets, emerging targets beyond BCMA, and the potential emergence of quadruplets, venetoclax, and antiviral therapy in amyloidosis.

Treatment Patterns Differ by Non–Biologic Factors in Undifferentiated Pleomorphic Sarcoma

July 19th 2021

Treatment patterns differed for patients with metastatic undifferentiated pleomorphic sarcoma based on disease characteristics, age, race, combined household income, and treatment facility.

Unique Mechanism of Action Positions Plinabulin as a Preventive and Active Therapy in Breast Cancer, NSCLC

July 19th 2021

The highly differentiated mechanism of action of plinabulin, an investigational, first-in-class, selective immunomodulating microtubule binding agent, has positioned the drug as a potential preventive treatment for chemotherapy-induced neutropenia, as well as an anticancer agent in non–small cell lung cancer.

Chemoimmunotherapy Shakes Up Metastatic and Early-Stage TNBC

July 17th 2021

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

Pevonedistat Plus HMAs Provides a Promising Strategy in Higher-Risk MDS

July 16th 2021

Daniel Pollyea, MD, MS, discusses the current management of patients with higher-risk myelodysplastic syndrome, the data noted so far with pevonedistat in this paradigm, and other therapies positioned to improve outcomes for this patient population.

Advances Propel Lung Cancer Paradigms Forward to Improved Outcomes and Quality of Life

July 15th 2021

Among a plethora of novel immunotherapeutic and targeted agents, the treatment landscapes for small cell lung cancer and non–small cell lung cancer have witnessed a rapid expansion that has led to improved survival and quality of life for patients, including a wider range of patients who harbor molecular abnormalities.

CDK4/6 Inhibitors Show Hints of Activity in Early-Stage HR+/HER2- Breast Cancer

July 12th 2021

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

Urologic Care Rates Decline Across US Demographics During Height of COVID-19 Pandemic

July 9th 2021

The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.

Usmani Underscores New and Updated Data Across Myeloma Paradigm

July 9th 2021

Although the armamentarium of multiple myeloma is rich with available treatment options, novel triplet regimens, maintenance therapies, and targets beyond BCMA are further expanding the paradigm across the newly diagnosed, early-relapse, and late-relapse disease states.

Survival Advantages in Metastatic Breast Cancer Move the Needle Toward Curative-Intent Strategies

July 8th 2021

Heather L. McArthur, MD, MPH, discusses key advances in breast cancer regarding CDK4/6 inhibitors, PI3K inhibitors, and subcutaneous formulations of standard treatments.

In-Home Infusions Could Continue to Bridge Disparities in Cancer Care

July 8th 2021

A silver lining of the COVID-19 pandemic has been the rapid uptake of telemedicine and virtual health care for patients with cancer.

MET Inhibition Looks to Advance NSCLC Treatment Landscape

July 6th 2021

Paul K. Paik, MD, discusses the clinical implications of tepotinib on the non–small cell lung cancer armamentarium.

Long-Term Data Showcase the Clinical Utility of Fixed-Duration Venetoclax/Obinutuzumab in Treatment-Naïve CLL

July 6th 2021

Fixed-duration venetoclax plus obinutuzumab demonstrated prolonged remissions compared with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.

Phase 3 MOMENTUM Study Completes Enrollment in Myelofibrosis

July 1st 2021

Enrollment to the pivotal phase 3 MOMENTUM trial, which is evaluating the novel JAK1/2 and ACVR1/ALK2 inhibitor momelotinib vs danazol in patients with symptomatic myelofibrosis and anemia, has completed.